Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gw590735. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 20/20 | 1.00 |
| ▸ | PPARD | Q03181 | 9/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582310 | 0.92 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL6582529 | 0.92 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL6582462 | 0.91 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL18645313 | 0.91 | PPARA (0.83) | PPARAPPARDPPARG | |
| SCHEMBL6582584 | 0.91 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL6582904 | 0.90 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL6584498 | 0.90 | PPARA (1.00) | PPARAPPARDPPARG | |
| SCHEMBL5185069 | 0.90 | PPARA (0.82) | PPARAPPARDPPARG | |
| SCHEMBL7465084 | 0.90 | PPARA (0.94) | PPARAPPARDPPARG | |
| SCHEMBL6580471 | 0.89 | PPARA (0.87) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2024251233-A1 | USE OF PPAR FULL AGONIST IN COMBINATION WITH THR-β AGONIST IN RESISTING OF METABOLIC-RELATED DISEASES | 成都微芯药业有限公司 | 2024-12-12 | — | — | WO | claimed |
| US-20240398905-A1 | COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-05 | — | — | US | claimed |
| US-11951158-B2 | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | LINDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2024-04-09 | — | — | US | claimed |
| US-20240034761-A1 | REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2024-02-01 | — | — | US | claimed |
| CN-116568802-A | In vitro method for preparing mature red blood cells | 西湖生物医药科技(上海)有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2023072010-A1 | USE OF PPAR AGONIST IN PREPARATION OF DRUG FOR TREATING ACUTE MYELOID LEUKEMIA | 厦门大学附属第一医院 | 2023-05-04 | — | — | WO | claimed |
| CN-115068618-A | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof | 厦门大学附属第一医院 | 2022-09-20 | — | — | CN | claimed |
| WO-2022192042-A2 | REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS | MASCARENHAS DESMOND (US) | 2022-09-15 | — | — | WO | claimed |
| CN-114949230-A | Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof | 厦门大学附属第一医院 | 2022-08-30 | — | — | CN | claimed |
| US-20100240627-A1 | COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | UNIVERSITEIT GENT | 2010-09-23 | — | — | US | claimed |
| US-20090111782-A1 | COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | GHENT UNIVERSITY (BE) | 2009-04-30 | — | — | US | claimed |
| US-20070202179-A1 | Low Dose Pharmaceutical Products | SMITHKLINE BEECHAM CORPORATION | 2007-08-30 | — | — | US | claimed |
| EP-1244642-B1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS HPPAR ALPHA ACTIVATORS | GLAXO GROUP LTD (GB) | 2004-04-28 | — | — | EP | claimed |
| US-6518290-B1 | Compounds that activate or otherwise interact with one or more of the PPARs have been implicated in the regulation of triglyceride and cholesterol levels in animal models | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | claimed |
| EP-1244642-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2002-10-02 | — | — | EP | claimed |
| WO-2001040207-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2001-06-07 | — | — | WO | claimed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2002046174-A1 | 1, 2, 4-OXADIAZOLE DERIVATIVES AS HPPAR ALPHA AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001040207-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202179-A1 | Low Dose Pharmaceutical Products | UGT1A7, UGT1A6, CYP3A7 | PPARA 1266/4885PPARD 834/4885PPARG 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.